Perspective Therapeutics, Inc.CATX

$2.95-0.03 (-1.01%)
AMEXHealthcare24:00 UTC

Company snapshot

Market Cap
$3M
Micro-cap
-99%
2016 — today
10-Year Price
-60%
2016 — today
52-Week Range
$2.05$5.65
Current $2.95· 25%

Perspective Therapeutics, Inc., including its various operations, specializes in the comprehensive lifecycle – from development and manufacturing to sales and marketing – of radiopharmaceutical products and medical devices. These advanced solutions are designed to treat cancer and other serious malignant conditions, serving markets both within the United States and globally. A flagship product offered by the company is its CS-1 Cesium-131 brachytherapy seeds. This treatment is specifically utilized for a broad range of cancers, such as those impacting the prostate, brain, lung, head and neck regions, gynecological system, pelvic/abdominal areas, and colorectal tissues. The company distributes its products to medical facilities and physician practices equipped with surgical capabilities. The entity originally operated under the name Isoray, Inc., before officially adopting the name Perspective Therapeutics, Inc. in February 2022. Founded in 1998, the company maintains its corporate headquarters in Richland, Washington.

Valuation in context

P/E ratio
-0.1
N/A
Not meaningful — company is unprofitable
P/B ratio
0.0
Near historic low
Near historic low — last 10 years
FCF Yield
-3,511.5%
Near historic low
Near historic low — last 10 years
Free · No credit card needed

Get alerted when CATX is cheap

Set a free alert — we'll push you when P/E, yield, or other metrics cross a historical threshold.